ACRS
Aclaris Therapeutics, Inc.
Price Chart
Latest Quote
$3.61
Current Price| Previous Close | $3.51 |
| Open | $3.48 |
| Day High | $3.73 |
| Day Low | $3.38 |
| Volume | 1,707,336 |
Stock Information
| Shares Outstanding | 108.35M |
| Total Debt | $2.24M |
| Cash Equivalents | $95.91M |
| Revenue | $15.74M |
| Net Income | $-141.68M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $391.13M |
| EPS (TTM) | $-1.58 |
| Exchange | NMS |
đ Custom Metrics & Score
Score: 13/42| Debt to Equity | 0.42 |
| Debt to Earnings | 19.86 |
| Current Ratio | 3.99 |
| Quick Ratio | 3.61 |
| Avg Revenue Growth | 44.22% |
| Profit Margin | -705.48% |
| Return on Equity | -84.90% |
| Avg FCF Growth | 1.70% |
| FCF Yield | -14.32% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $3.61 | 1,747,178 |
| 2026-01-30 | $3.51 | 1,144,700 |
| 2026-01-29 | $3.43 | 761,500 |
| 2026-01-28 | $3.51 | 1,571,400 |
| 2026-01-27 | $3.87 | 1,207,500 |
| 2026-01-26 | $3.82 | 2,382,400 |
| 2026-01-23 | $4.50 | 2,558,900 |
| 2026-01-22 | $4.53 | 2,983,100 |
| 2026-01-21 | $4.42 | 5,064,000 |
| 2026-01-20 | $4.43 | 34,893,400 |
| 2026-01-16 | $2.62 | 765,900 |
| 2026-01-15 | $2.67 | 501,400 |
| 2026-01-14 | $2.74 | 398,100 |
| 2026-01-13 | $2.71 | 565,100 |
| 2026-01-12 | $2.66 | 1,255,800 |
| 2026-01-09 | $2.64 | 495,800 |
| 2026-01-08 | $2.68 | 772,800 |
| 2026-01-07 | $2.68 | 1,099,500 |
| 2026-01-06 | $2.65 | 3,045,900 |
| 2026-01-05 | $2.65 | 1,022,300 |
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
đ° Latest News
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052
TipRanks âĸ 2026-01-13T12:44:41Z
3 Promising Penny Stocks With A Market Cap Below $400M
Simply Wall St. âĸ 2025-12-30T12:05:18Z
Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks
Simply Wall St. âĸ 2025-11-20T12:05:11Z
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Zacks âĸ 2025-11-06T13:05:02Z
Aclaris: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-06T12:08:47ZCorcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates
Zacks âĸ 2025-11-04T23:25:02Z
Aclaris Therapeutics (NASDAQ:ACRS) adds US$40m to market cap in the past 7 days, though investors from three years ago are still down 83%
Simply Wall St. âĸ 2025-11-02T12:27:22Z
What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now?
Zacks âĸ 2025-10-21T16:00:02Z
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
Simply Wall St. âĸ 2025-10-12T12:49:40Z
Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight
Insider Monkey âĸ 2025-09-21T13:13:18Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $15,458,000 | $18,081,000 | $11,960,000 | $4,713,000 |
| Cost Of Revenue | $15,458,000 | $18,081,000 | $11,960,000 | $4,713,000 |
| Total Revenue | $18,720,000 | $31,249,000 | $29,752,000 | $6,761,000 |
| Operating Revenue | $18,720,000 | $31,249,000 | $29,495,000 | $6,639,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $71,247,000 | $147,563,000 | $114,906,000 | $72,145,000 |
| Other Income Expense | $-79,538,000 | $27,466,000 | $-1,754,000 | $-25,481,000 |
| Other Non Operating Income Expenses | $9,867,000 | $8,509,000 | $2,946,000 | $-1,142,000 |
| Operating Expense | $55,789,000 | $129,482,000 | $102,946,000 | $67,432,000 |
| General And Administrative Expense | $22,203,000 | $31,098,000 | $25,133,000 | $23,619,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-132,065,000 | $-88,481,000 | $-86,908,000 | $-90,865,000 |
| Normalized Income | $-42,660,000 | $-107,359,695 | $-82,208,000 | $-66,526,000 |
| Net Income From Continuing And Discontinued Operation | $-132,065,000 | $-88,481,000 | $-86,908,000 | $-90,865,000 |
| Total Operating Income As Reported | $-141,932,000 | $-97,357,000 | $-89,854,000 | $-89,723,000 |
| Net Income Common Stockholders | $-132,065,000 | $-88,481,000 | $-86,908,000 | $-90,865,000 |
| Net Income | $-132,065,000 | $-88,481,000 | $-86,908,000 | $-90,865,000 |
| Net Income Including Noncontrolling Interests | $-132,065,000 | $-88,481,000 | $-86,908,000 | $-90,865,000 |
| Net Income Continuous Operations | $-132,065,000 | $-88,481,000 | $-86,908,000 | $-90,865,000 |
| Pretax Income | $-132,065,000 | $-88,848,000 | $-86,908,000 | $-90,865,000 |
| Special Income Charges | $-89,405,000 | $18,957,000 | $-4,700,000 | $-24,339,000 |
| Operating Income | $-52,527,000 | $-116,314,000 | $-85,154,000 | $-65,384,000 |
| Gross Profit | $3,262,000 | $13,168,000 | $17,792,000 | $2,048,000 |
| Net Income Discontinuous Operations | - | - | $0 | $0 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.71 | $-1.27 | $-1.33 | $-1.60 |
| Basic EPS | $-1.71 | $-1.27 | $-1.33 | $-1.60 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $78,305 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $37,685,000 | $-134,408,000 | $-79,657,000 | $-40,122,000 |
| Total Unusual Items | $-89,405,000 | $18,957,000 | $-4,700,000 | $-24,339,000 |
| Total Unusual Items Excluding Goodwill | $-89,405,000 | $18,957,000 | $-4,700,000 | $-24,339,000 |
| Reconciled Depreciation | $807,000 | $863,000 | $797,000 | $923,000 |
| EBITDA (Bullshit earnings) | $-51,720,000 | $-115,451,000 | $-84,357,000 | $-64,461,000 |
| EBIT | $-52,527,000 | $-116,314,000 | $-85,154,000 | $-65,384,000 |
| Diluted Average Shares | $77,296,665 | $69,808,855 | $65,213,944 | $56,730,583 |
| Basic Average Shares | $77,296,665 | $69,808,855 | $65,213,944 | $56,730,583 |
| Diluted NI Availto Com Stockholders | $-132,065,000 | $-88,481,000 | $-86,908,000 | $-90,865,000 |
| Tax Provision | $0 | $-367,000 | $0 | $0 |
| Write Off | $0 | $1,314,000 | $0 | - |
| Restructuring And Mergern Acquisition | $89,405,000 | $-20,271,000 | $4,700,000 | $24,339,000 |
| Research And Development | $33,586,000 | $98,384,000 | $77,813,000 | $43,813,000 |
| Selling General And Administration | $22,203,000 | $31,098,000 | $25,133,000 | $23,619,000 |
| Other Gand A | $8,634,000 | $10,797,000 | $8,962,000 | $23,619,000 |
| Salaries And Wages | $13,569,000 | $20,301,000 | $16,171,000 | $14,100,000 |
| Impairment Of Capital Assets | - | $6,629,000 | $0 | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $155,554,000 | $157,179,000 | $190,648,000 | $190,293,000 |
| Total Assets | $220,327,000 | $197,405,000 | $254,596,000 | $251,211,000 |
| Total Non Current Assets | $94,376,000 | $68,549,000 | $23,046,000 | $46,179,000 |
| Other Non Current Assets | $3,066,000 | $4,158,000 | $2,732,000 | $3,554,000 |
| Investmentin Financial Assets | $90,302,000 | $62,771,000 | $12,242,000 | $34,242,000 |
| Current Assets | $125,951,000 | $128,856,000 | $231,550,000 | $205,032,000 |
| Other Current Assets | $12,039,000 | $9,452,000 | $13,495,000 | $12,995,000 |
| Receivables | $318,000 | $298,000 | $484,000 | $623,000 |
| Accounts Receivable | $318,000 | $298,000 | $484,000 | $623,000 |
| Cash Cash Equivalents And Short Term Investments | $113,594,000 | $119,106,000 | $217,571,000 | $191,414,000 |
| Cash And Cash Equivalents | $24,570,000 | $39,878,000 | $45,277,000 | $27,349,000 |
| Goodwill And Other Intangible Assets | - | $269,000 | $6,973,000 | $7,048,000 |
| Other Intangible Assets | - | $269,000 | $6,973,000 | $7,048,000 |
| Prepaid Assets | - | - | - | $12,995,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | - | $426,000 | $684,000 | $693,000 |
| Current Debt And Capital Lease Obligation | - | $426,000 | $684,000 | $693,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $64,773,000 | $40,226,000 | $56,975,000 | $53,870,000 |
| Total Non Current Liabilities Net Minority Interest | $33,177,000 | $9,274,000 | $35,037,000 | $30,939,000 |
| Other Non Current Liabilities | $13,139,000 | $9,274,000 | $34,670,000 | $30,572,000 |
| Non Current Deferred Liabilities | $20,038,000 | $0 | $367,000 | $367,000 |
| Current Liabilities | $31,596,000 | $30,952,000 | $21,938,000 | $22,931,000 |
| Other Current Liabilities | $2,683,000 | $2,628,000 | $2,202,000 | $2,202,000 |
| Current Deferred Liabilities | $7,817,000 | $0 | - | - |
| Payables And Accrued Expenses | $16,117,000 | $24,414,000 | $13,757,000 | $15,647,000 |
| Payables | $4,690,000 | $8,878,000 | $10,351,000 | $9,985,000 |
| Accounts Payable | $4,690,000 | $8,878,000 | $10,351,000 | $9,985,000 |
| Non Current Deferred Taxes Liabilities | - | $0 | $367,000 | $367,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $155,554,000 | $157,179,000 | $197,621,000 | $197,341,000 |
| Total Equity Gross Minority Interest | $155,554,000 | $157,179,000 | $197,621,000 | $197,341,000 |
| Stockholders Equity | $155,554,000 | $157,179,000 | $197,621,000 | $197,341,000 |
| Gains Losses Not Affecting Retained Earnings | $97,000 | $-106,000 | $-897,000 | $-224,000 |
| Other Equity Adjustments | $97,000 | $-106,000 | $-897,000 | $-224,000 |
| Retained Earnings | $-902,861,000 | $-770,796,000 | $-682,315,000 | $-595,407,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $107,850,124 | $70,894,889 | $66,688,647 | $61,228,446 |
| Share Issued | $107,850,124 | $70,894,889 | $66,688,647 | $61,228,446 |
| Tangible Book Value | $155,554,000 | $157,179,000 | $190,648,000 | $190,293,000 |
| Invested Capital | $155,554,000 | $157,179,000 | $197,621,000 | $197,341,000 |
| Working Capital | $94,355,000 | $97,904,000 | $209,612,000 | $182,101,000 |
| Total Capitalization | $155,554,000 | $157,179,000 | $197,621,000 | $197,341,000 |
| Additional Paid In Capital | $1,058,317,000 | $928,080,000 | $880,832,000 | $792,971,000 |
| Capital Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $20,038,000 | $0 | - | - |
| Current Deferred Revenue | $3,890,000 | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | $4,979,000 | $3,910,000 | $5,295,000 | $4,389,000 |
| Current Accrued Expenses | $11,427,000 | $15,536,000 | $3,406,000 | $5,662,000 |
| Investments And Advances | $90,302,000 | $62,771,000 | $12,242,000 | $34,242,000 |
| Available For Sale Securities | $90,302,000 | $62,771,000 | $12,242,000 | $34,242,000 |
| Net PPE | $1,008,000 | $1,620,000 | $1,099,000 | $1,335,000 |
| Accumulated Depreciation | $-4,805,000 | $-4,162,000 | $-4,035,000 | $-3,393,000 |
| Gross PPE | $5,813,000 | $5,782,000 | $5,134,000 | $4,728,000 |
| Leases | $817,000 | $817,000 | $1,123,000 | $1,123,000 |
| Other Properties | $3,137,000 | $3,154,000 | $2,010,000 | $1,605,000 |
| Machinery Furniture Equipment | $1,859,000 | $1,811,000 | $2,001,000 | $2,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $89,024,000 | $79,228,000 | $172,294,000 | $164,065,000 |
| Treasury Shares Number | - | $0 | - | - |
| Capital Lease Obligations | - | $426,000 | $684,000 | $693,000 |
| Current Capital Lease Obligation | - | $426,000 | $684,000 | $693,000 |
| Other Investments | - | - | - | $34,242,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-56,006,000 | $-79,634,000 | $-68,172,000 | $-52,442,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-20,075,000 | $-78,325,000 | $-67,567,000 | $-52,134,000 |
| Cash Flow From Continuing Operating Activities | $-20,075,000 | $-78,325,000 | $-67,567,000 | $-52,134,000 |
| Operating Gains Losses | - | - | - | $752,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-35,931,000 | $-1,309,000 | $-605,000 | $-308,000 |
| Investing Cash Flow | $-69,769,000 | $46,220,000 | $12,628,000 | $-167,632,000 |
| Cash Flow From Continuing Investing Activities | $-69,769,000 | $46,220,000 | $12,628,000 | $-167,632,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $74,913,000 | $26,714,000 | $72,744,000 | $238,200,000 |
| Financing Cash Flow | $74,536,000 | $26,706,000 | $72,867,000 | $225,052,000 |
| Cash Flow From Continuing Financing Activities | $74,536,000 | $26,706,000 | $72,867,000 | $225,052,000 |
| Net Other Financing Charges | $-409,000 | $-102,000 | $-34,000 | $-3,124,000 |
| Net Common Stock Issuance | $74,913,000 | $26,714,000 | $72,744,000 | $238,200,000 |
| Common Stock Issuance | $74,913,000 | $26,714,000 | $72,744,000 | $238,200,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| End Cash Position | $24,570,000 | $39,878,000 | $45,277,000 | $27,349,000 |
| Beginning Cash Position | $39,878,000 | $45,277,000 | $27,349,000 | $22,063,000 |
| Changes In Cash | $-15,308,000 | $-5,399,000 | $17,928,000 | $5,286,000 |
| Proceeds From Stock Option Exercised | $32,000 | $94,000 | $157,000 | $1,459,000 |
| Net Investment Purchase And Sale | $-33,838,000 | $47,529,000 | $13,233,000 | $-167,324,000 |
| Sale Of Investment | $86,144,000 | $183,204,000 | $177,986,000 | $67,829,000 |
| Purchase Of Investment | $-119,982,000 | $-135,675,000 | $-164,753,000 | $-235,153,000 |
| Net Intangibles Purchase And Sale | $-35,810,000 | $0 | - | - |
| Purchase Of Intangibles | $-35,810,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-121,000 | $-1,309,000 | $-605,000 | $-308,000 |
| Purchase Of PPE | $-121,000 | $-1,309,000 | $-605,000 | $-308,000 |
| Change In Working Capital | $10,922,000 | $9,389,000 | $-1,195,000 | $-1,343,000 |
| Change In Other Working Capital | $23,927,000 | - | - | - |
| Change In Payables And Accrued Expense | $-8,130,000 | $10,518,000 | $960,000 | $4,125,000 |
| Change In Accrued Expense | $-3,942,000 | $11,991,000 | $592,000 | $470,000 |
| Change In Payable | $-4,188,000 | $-1,473,000 | $368,000 | $3,655,000 |
| Change In Account Payable | $-4,188,000 | $-1,473,000 | $368,000 | $3,655,000 |
| Change In Prepaid Assets | $-4,855,000 | $-1,315,000 | $-2,294,000 | $-5,617,000 |
| Change In Receivables | $-20,000 | $186,000 | $139,000 | $149,000 |
| Changes In Account Receivables | $-20,000 | $186,000 | $139,000 | $149,000 |
| Other Non Cash Items | $89,405,000 | $-20,271,000 | $4,700,000 | $24,339,000 |
| Stock Based Compensation | $10,856,000 | $20,542,000 | $15,039,000 | $14,060,000 |
| Deferred Tax | $0 | $-367,000 | $0 | $0 |
| Deferred Income Tax | $0 | $-367,000 | $0 | $0 |
| Depreciation Amortization Depletion | $807,000 | $863,000 | $797,000 | $923,000 |
| Depreciation And Amortization | $807,000 | $863,000 | $797,000 | $923,000 |
| Net Income From Continuing Operations | $-132,065,000 | $-88,481,000 | $-86,908,000 | $-90,865,000 |
| Repayment Of Debt | - | $0 | $0 | $-11,483,000 |
| Net Issuance Payments Of Debt | - | $0 | $0 | $-11,483,000 |
| Net Long Term Debt Issuance | - | $0 | $0 | $-11,483,000 |
| Long Term Debt Payments | - | $0 | $0 | $-11,483,000 |
| Asset Impairment Charge | - | $6,629,000 | $0 | $0 |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
| Gain Loss On Sale Of Business | - | - | - | $0 |